Xerion Healthcare Limited

Although great progress has been made in the treatment of some common cancers there remain many where there has been little improvement over decades. One of these is aggressive brain tumours, which have a median survival time of 14.6 months -- a figure that has not improved over the last four decades. The current best-supported care is surgery, which remo...

Although great progress has been made in the treatment of some common cancers there remain many indications where there has been little improvement in care over decades. The most difficult tumours tend to be inoperable with treatment options limited to chemotherapy and radiotherapy. Chemotherapy is administered systemically and a balance between toxicity ...

Xerion Healthcare Ltd ("Xerion") have developed a highly innovative and cost-effective nanoparticle technology, Oxilia. This technology is intended to augment standard radiotherapy to provide more effective treatment for patients with inoperable cancers, with the primary focus on head and neck (HNC) and pancreatic cancers. Current therapies are not adequa...

"Application defined by a partnership: the lead applicant has an advanced ultrasound ""driven"" needle that greatly improves the accuracy of delivering medicines to deep tissues (improved tissue penetration and highly visible on ultrasound scanners); the partner has a nanotechnology based agent that generates highly localised free radicals to enhance the ...

The project will develop nanoparticles of complex semiconductors that will be injected into tumours and act to enhance the effectiveness of radiotherapy treatment of cancer. Radiotherapy treatment is often limited by the toxicity of the treatment to healthy tissues surrounding the tumour, meaning that simply increasing the dose is not an option. Xerion He...